| Enrolling By Invitation | Optimal Surveillance Strategy After Positive FIT and Negative Colonoscopy NCT07470658 | National Taiwan University Hospital | — |
| Recruiting | A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell NCT07321106 | Cartography Biosciences | Phase 1 |
| Recruiting | Irinotecan Liposome Plus Capecitabine and Enronsubemab Combined With Short-course Radiotherapy for Neoadjuvant NCT07281157 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Not Yet Recruiting | Assessment of the Dose Safety and Efficacy of Serine Combined With Fluorouracil Drugs NCT07178613 | The First Affiliated Hospital of Xinxiang Medical College | Phase 1 |
| Not Yet Recruiting | Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phas NCT07106034 | Shanghai Pudong Hospital | Phase 2 |
| Recruiting | Trial of ProAgio in Advanced/Metastatic Colorectal Cancer NCT06867822 | University of Alabama at Birmingham | Phase 1 |
| Not Yet Recruiting | TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer NCT06589830 | Suzhou Teligene Ltd. | Phase 2 |
| Not Yet Recruiting | A Study of Cetuximabβ Combined With Envolimab and mFOLFOX6 in Subjects With Advanced Colorectal Cancer NCT07000305 | Tao Zhang | Phase 2 |
| Recruiting | Clinical Study on the First-line Treatment of Advanced Colorectal Cancer With Simultaneous Infusion of Levozol NCT07391618 | Chinese PLA General Hospital | Phase 2 |
| Recruiting | A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemothe NCT06885385 | Shanghai Junshi Bioscience Co., Ltd. | Phase 2 |
| Active Not Recruiting | SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal Metastases NCT06940921 | Zhang Tao | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Multicenter, Open Phase IIb Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Tre NCT06838546 | Tasly Biopharmaceuticals Co., Ltd. | Phase 2 |
| Recruiting | Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Ce NCT06369259 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | The Role of 18F-FDG and 68Ga-FAPI PET/CT in the Diagnosis and the Efficacy Evaluation of Advanced Colorectal C NCT06601075 | Ruijin Hospital | — |
| Recruiting | Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer NCT06824064 | Riboscience, LLC. | Phase 2 |
| Not Yet Recruiting | SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcin NCT06666166 | Yunpeng Liu | Phase 2 |
| Recruiting | A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advan NCT06585488 | BeiGene | Phase 1 |
| Active Not Recruiting | Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had NCT06199973 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 3 |
| Unknown | A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal Cancer NCT06200363 | West China Hospital | Phase 1 |
| Not Yet Recruiting | Fruquintinib Combined With Chemotherapy as Third-line /Third-line+ Treatment in Advanced Colorectal Cancer NCT05928312 | Zhejiang Cancer Hospital | N/A |
| Not Yet Recruiting | Cetuximab in Combination With Dabrafenib and Tislelizumab in BRAF Mutated Treatment of Advanced Colorectal Can NCT05963087 | Zhejiang Cancer Hospital | N/A |
| Recruiting | Chemokine and Co-stimulatory Molecule-modified Mesenchymal Stem Cells for the Treatment of Advanced Colorectal NCT06446050 | Shanghai East Hospital | EARLY_Phase 1 |
| Completed | Rehabilitation for People With Advanced Cancer NCT05424068 | University Health Network, Toronto | N/A |
| Unknown | LEAC-102 for Advanced Colorectal Cancer NCT02826837 | Taiwan Leader Biotech Corp. | Phase 1 / Phase 2 |
| Unknown | Circulating Tumor DNA Guided Therapeutic Strategies for CRC Patients With Small Pulmonary Nodules NCT05495672 | Junjie Peng | N/A |
| Not Yet Recruiting | Efficacy, Safety and Exploratory Clinical Study of Bevacizumab Combined With Oxaliplatin and TAS-102 in First- NCT05364489 | The First Affiliated Hospital of Zhengzhou University | Phase 2 |
| Recruiting | A Prospective Cohort Study of Advanced Colorectal Cancer Treated With Oxaliplatin and Irinotecan. NCT05731336 | Sun Yat-sen University | — |
| Active Not Recruiting | JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mu NCT05194995 | Allist Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Unknown | Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study NCT04764006 | Fujian Cancer Hospital | Phase 2 |
| Unknown | IMC001 for Clinical Research on Advanced Digestive System Malignancies NCT05028933 | Zhejiang University | Phase 1 |
| Unknown | Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in mCRC NCT05077839 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Unknown | Anlotinib Combined With mXELIRI as Second-line Treatment of Advanced Colorectal Cancer NCT05035914 | Guangzhou University of Traditional Chinese Medicine | Phase 1 / Phase 2 |
| Active Not Recruiting | Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS NCT04793958 | Mirati Therapeutics Inc. | Phase 3 |
| Unknown | Surufatinib Combine With Immunotherapy and Chemotherapy for Second-line Treatment in Advanced Colorectal Cance NCT04929652 | Jiangsu Cancer Institute & Hospital | Phase 1 / Phase 2 |
| Completed | Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer NCT04744831 | Daiichi Sankyo | Phase 2 |
| Unknown | Second-line Surufatinib Combined With Chemotherapy in Advanced CRC NCT04734249 | Fujian Cancer Hospital | Phase 2 |
| Unknown | Regorafenib Treatment Patterns and Survival Outcomes in Advanced Colorectal Cancer: A Real-world Study NCT04835324 | Chinese Academy of Medical Sciences | — |
| Unknown | A Study of AL2846 Capsule Combined With Standard Chemotherapy Regimen in Subjects With Advanced Colorectal Can NCT04337879 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer NCT04324476 | Jiangsu Cancer Institute & Hospital | Phase 2 |
| Completed | Identification of New Patient Stratification Tools in MSS RAS mt mCRC NCT03699111 | Cancer Trials Ireland | — |
| Unknown | Folfiri/aflIbercept in Metastatic coloreCTal Cancer patIents With RAS Validated Wild typE Status NCT04252456 | Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente | N/A |
| Withdrawn | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Colorectal Cancer NCT03524274 | Fuda Cancer Hospital, Guangzhou | Phase 2 |
| Terminated | Anti-EGFR Therapy Rechallenge in Combination With Chemotherapy in Patients With Advanced Colorectal Cancer NCT03311750 | Hellenic Cooperative Oncology Group | Phase 2 |
| Completed | Clinical Trial of PM60184 in Advanced Colorectal Cancer After Standard Treatment NCT03427268 | PharmaMar | Phase 2 |
| Unknown | Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer NCT03126071 | Jiangsu Cancer Institute & Hospital | Phase 2 |
| Unknown | Efficacy and Safety Evaluation of Traditional Chinese Medicine in the Treatment of Advanced Colorectal Cancer NCT02923622 | Xiyuan Hospital of China Academy of Chinese Medical Sciences | — |
| Unknown | Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer NCT02619435 | National Cancer Institute, Naples | Phase 2 |
| Completed | Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer NCT02227667 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | A Phase 3 Study to Evaluate Xilonix as an Anticancer Therapy in Patients With Symptomatic Colorectal Cancer NCT02138422 | Janssen Research & Development, LLC | Phase 3 |
| Withdrawn | A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer NCT02038699 | Jazz Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Screening Platform for Clinical Trials in Advanced Colorectal Cancer NCT01723969 | European Organisation for Research and Treatment of Cancer - EORTC | — |
| Completed | Effect of Curcumin on Dose Limiting Toxicity and Pharmacokinetics of Irinotecan in Patients With Solid Tumors NCT01859858 | UNC Lineberger Comprehensive Cancer Center | Phase 1 |
| Completed | ANGIOPREDICT. ICORG 12-16, V3 NCT01822444 | Cancer Trials Ireland | — |
| Completed | A Phase II Trial of Salvage Treatment With Gemcitabine and S-1 Combination in Patients With Heavily Treated Ad NCT01929421 | Gachon University Gil Medical Center | Phase 2 |
| Unknown | Study of Nimotuzumab to Treat Colorectal Cancer NCT00972465 | Peking University | Phase 2 |
| Terminated | Methotrexate in Metastatic Colorectal Cancer With MSH2 Deficiency NCT00952016 | Royal Marsden NHS Foundation Trust | Phase 2 |
| Unknown | Oxaliplatin, Capecitabine and Endostar as First Line Treatment for Patients With Advanced Colorectal Cancer NCT00853684 | Shanghai Jiao Tong University School of Medicine | Phase 2 |
| Terminated | Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer NCT00824161 | Taiho Pharmaceutical Co., Ltd. | Phase 2 |
| Unknown | Efficacy Study of TKcell in Advanced Colorectal Cancer NCT00854971 | Binex | Phase 1 / Phase 2 |
| Completed | Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat NCT00707889 | AbbVie (prior sponsor, Abbott) | Phase 2 |
| Completed | Efficacy Analysis of Cetuximab Plus Irinotecan in Patients With Wild-type KRAS Without Regard to Epidermal Gro NCT00637091 | Asan Medical Center | Phase 2 |
| Completed | A Pilot Study of PPX in Women With Metastatic Colorectal Cancer NCT00598247 | University of Southern California | Phase 1 |
| Terminated | Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer NCT01271166 | Novartis Pharmaceuticals | Phase 1 |
| Completed | A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in NCT00309179 | Eisai Inc. | Phase 2 |
| Completed | A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer NCT00498407 | Clavis Pharma | Phase 2 |
| Completed | Chemoradiation for Locally Advanced and Low Rectal Cancers: Avastin-Capecitabine-Oxaliplatin-Radiation REctal NCT00386828 | British Columbia Cancer Agency | Phase 2 |
| Completed | High Dose Simplified Folfiri in Advanced Colorectal Cancer: a Multicentre Phase II Study NCT00286000 | University Hospital, Ghent | Phase 2 |
| Completed | Sequential Versus Combination Chemotherapy in Advanced Colorectal Carcinoma NCT00312000 | Dutch Colorectal Cancer Group | Phase 3 |